Treatment of Small Cell Lung Cancer by Eight Weeks Chemotherapy

Overview

Journal Med Oncol Tumor Pharmacother

Specialties Oncology
Pharmacology

Date 1989 Jan 1

PMID 2559264

Authors

S M Crawford

D Parker

M G Glaser

B M Southcott

R H Begent

G J Rustin

E S Newlands

A J Ward

K D Bagshawe

Affiliations

Soon will be listed here.

Abstract

Eighty-two patients with small cell lung cancer (SCLC), 32 with limited disease, were treated with alternating chemotherapy. Eight courses were administered at weekly intervals, and responding patients received radiotherapy to sites of bulk disease. Overall response rate was 76.8%. Overall median survival was 265 days, 408 days in patients with limited disease. The median symptom free period after chemotherapy was completed was 123 days. These results are comparable with those in reports of chemotherapy of longer duration and warrant the further investigation of short duration treatment in this disease.

References

Smyth J, Fowlie S, Gregor A, Crompton G, Busuttil A, Leonard R . The impact of chemotherapy on small cell carcinoma of the bronchus. Q J Med. 1986; 61(234):969-76. View

Slevin M, Harvey V, Ponder B, Messina S, Lister T, MALPAS J . Small-cell lung carcinoma: survival after combination chemotherapy, radiotherapy or symptomatic treatment. Br J Dis Chest. 1983; 77(4):381-9. View

Osterlind K, Sorenson S, Hansen H, Dombernowsky P, Hirsch F, Hansen M . Continuous versus alternating combination chemotherapy for advanced small cell carcinoma of the lung. Cancer Res. 1983; 43(12 Pt 1):6085-9. View

Daniels J, Chak L, Sikic B, Lockbaum P, Kohler M, Carter S . Chemotherapy of small-cell carcinoma of lung: a randomized comparison of alternating and sequential combination chemotherapy programs. J Clin Oncol. 1984; 2(11):1192-9. DOI: 10.1200/JCO.1984.2.11.1192. View

Souhami R, Geddes D, Spiro S, Harper P, Tobias J, Mantell B . Radiotherapy in small cell cancer of the lung treated with combination chemotherapy: a controlled trial. Br Med J (Clin Res Ed). 1984; 288(6431):1643-6. PMC: 1441467. DOI: 10.1136/bmj.288.6431.1643. View

Lopez J, Mann J, Grapski R, Nassif E, Vannicola P, Krikorian J . Etoposide and cisplatin salvage chemotherapy for small cell lung cancer. Cancer Treat Rep. 1985; 69(4):369-71. View

Goldie J, Coldman A . A mathematic model for relating the drug sensitivity of tumors to their spontaneous mutation rate. Cancer Treat Rep. 1979; 63(11-12):1727-33. View

Johnson D, Einhorn L, Birch R, Vollmer R, Perez C, Krauss S . A randomized comparison of high-dose versus conventional-dose cyclophosphamide, doxorubicin, and vincristine for extensive-stage small-cell lung cancer: a phase III trial of the Southeastern Cancer Study Group. J Clin Oncol. 1987; 5(11):1731-8. DOI: 10.1200/JCO.1987.5.11.1731. View

Carroll K, Moussalli H, Brown D, Thatcher N . A comparison between a single agent short course chemotherapy regimen and a quadruple prolonged course regimen for small-cell bronchogenic carcinoma of limited extent. Br J Dis Chest. 1983; 77(2):171-8. DOI: 10.1016/0007-0971(83)90024-4. View

10.

Souhami R, Harper P, Linch D, Trask C, Goldstone A, Tobias J . High-dose cyclophosphamide with autologous marrow transplantation for small cell carcinoma of the bronchus. Cancer Chemother Pharmacol. 1983; 10(3):205-7. DOI: 10.1007/BF00255764. View

11.

Cantwell B, Bozzino J, Corris P, Harris A . The multidrug resistant phenotype in clinical practice; evaluation of cross resistance to ifosfamide and mesna after VP16-213, doxorubicin and vincristine (VPAV) for small cell lung cancer. Eur J Cancer Clin Oncol. 1988; 24(2):123-9. DOI: 10.1016/0277-5379(88)90242-8. View

12.

Thatcher N, Stout R, Smith D, Grotte G, Winson M, Bassett H . Three months treatment with chemotherapy and radiotherapy for small cell lung cancer. Br J Cancer. 1985; 52(3):327-32. PMC: 1977208. DOI: 10.1038/bjc.1985.197. View

13.

Klastersky J . Therapy of small cell lung cancer: anything new?. Eur J Cancer Clin Oncol. 1988; 24(2):107-12. DOI: 10.1016/0277-5379(88)90239-8. View

14.

Comis R . Small cell carcinoma of the lung. Cancer Treat Rev. 1982; 9(3):237-58. DOI: 10.1016/s0305-7372(82)80009-1. View

15.

Daugaard G, Hansen H, Rorth M . Phase II study of vindesine, cisplatin, and hexamethylmelamine (VCH) in small cell carcinoma of the lung. Cancer Treat Rep. 1984; 68(9):1179-81. View

16.

Thatcher N, James R, Steward W, Barber P, Feinmann D, Lawson B . Three months' treatment with cyclophosphamide, VP-16-213 followed by methotrexate and thoracic radiotherapy for small cell lung cancer. Cancer. 1985; 56(6):1332-6. DOI: 10.1002/1097-0142(19850915)56:6<1332::aid-cncr2820560619>3.0.co;2-e. View

17.

Morgan D, Gilson D, Fletcher J . Vincristine and etoposide: an effective chemotherapy regimen with reduced toxicity in extensive small-cell lung cancer. Eur J Cancer Clin Oncol. 1987; 23(6):619-21. DOI: 10.1016/0277-5379(87)90256-2. View

18.

Lowenbraun S, Birch R, Buchanan R, Krauss S, Durant J, Perez C . Combination chemotherapy in small cell lung carcinoma. A randomized study of two intensive regimens. Cancer. 1984; 54(11):2344-50. DOI: 10.1002/1097-0142(19841201)54:11<2344::aid-cncr2820541106>3.0.co;2-c. View

19.

Kessinger A, Foley J, LEMON H . Therapeutic management of small cell lung cancer. Fewer toxic reactions with lower chemotherapeutic drug dosages. JAMA. 1983; 250(23):3188-91. View

20.

Perez C, Einhorn L, Oldham R, Greco F, Cohen H, SILBERMAN H . Randomized trial of radiotherapy to the thorax in limited small-cell carcinoma of the lung treated with multiagent chemotherapy and elective brain irradiation: a preliminary report. J Clin Oncol. 1984; 2(11):1200-8. DOI: 10.1200/JCO.1984.2.11.1200. View